Log in

NASDAQ:ACOR - Acorda Therapeutics Stock Price, Forecast & News

$2.07
-0.08 (-3.72 %)
(As of 01/17/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.06
Now: $2.07▼
$2.18
50-Day Range
$1.60
MA: $2.01▼
$2.75
52-Week Range
$1.49
Now: $2.07▼
$17.41
Volume1.66 million shs
Average Volume4.09 million shs
Market Capitalization$99.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACOR
Previous Symbol
CUSIP00484M10
CIK1008848
Webhttp://www.acorda.com/
Phone914-347-4300

Debt

Debt-to-Equity Ratio1.33
Current Ratio3.42
Quick Ratio3.12

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$471.43 million
Price / Sales0.21
Cash Flow$2.27 per share
Price / Cash Flow0.91
Book Value$12.87 per share
Price / Book0.16

Profitability

EPS (Most Recent Fiscal Year)$1.82
Net Income$33.68 million
Net Margins-155.89%
Return on Equity-12.96%
Return on Assets-5.63%

Miscellaneous

Employees474
Outstanding Shares48,030,000
Market Cap$99.42 million
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:ACOR Rates by TradingView

Stock Trades Or Predictions (Ad)


Want to know which stocks should be on your radar this week? Every Sunday we send out the 3 Stock Trades that we predict will be big winners for the week ahead.

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) announced its quarterly earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.05. The biopharmaceutical company had revenue of $47.72 million for the quarter, compared to the consensus estimate of $43.23 million. Acorda Therapeutics had a negative net margin of 155.89% and a negative return on equity of 12.96%. Acorda Therapeutics's revenue for the quarter was down 66.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.17 EPS. View Acorda Therapeutics' Earnings History.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Acorda Therapeutics.

What guidance has Acorda Therapeutics issued on next quarter's earnings?

Acorda Therapeutics updated its FY 2020 Pre-Market earnings guidance on Wednesday, January, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $130-160 million, compared to the consensus revenue estimate of $143.9 million.

What price target have analysts set for ACOR?

7 Wall Street analysts have issued twelve-month price objectives for Acorda Therapeutics' stock. Their forecasts range from $1.40 to $12.00. On average, they expect Acorda Therapeutics' share price to reach $7.23 in the next twelve months. This suggests a possible upside of 249.4% from the stock's current price. View Analyst Price Targets for Acorda Therapeutics.

What is the consensus analysts' recommendation for Acorda Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acorda Therapeutics.

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:
  • 1. Stifel Nicolaus analysts commented, "Stifel analyst Paul Matteis lowered the price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) to $7.00 (from $12.00) while maintaining a Hold rating." (8/2/2019)
  • 2. According to Zacks Investment Research, "Acorda got a huge boost with the approval of Inbrija in the United States, slightly before the scheduled time period. The drug is also under review in the EU with a decision expected in 2019. Inbrija was launched in February and registered its first sales in the first quarter. Acorda is seeking collaborations on the ex-U.S. commercialization of Inbrija with potential partners both across Europe and Japan. However, its key multiple sclerosis drug Ampyra is facing a generic competition which is significantly hurting Acorda’s top-line. The company expects to see a persistent decline in Ampyra sales during the quarters ahead in 2019. Shares of Acorda have underperformed the industry in the year so far. Nonetheless, Acorda boasts a strong pipeline addressing a wide range of disorders. The restructuring initiative is also saving costs." (7/3/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating but raise our price target on ACOR to $20 from $19. On Thursday, Acorda reported 4Q18 financials and detailed future commercialization plans for Inbrija, including monthly WAC pricing of $950, ~25% higher than our projections. The company reported net Ampyra revenues of $64.2M, higher than consensus $46.8M, reflecting a steep decline from the prior quarter, but clearly not as bad as some expected (we were $75.8M). That said, we anticipate Amp revs to continue to decline and therefore do not include Amp sales in our valuation of ACOR shares. Going forward, we see Acorda’s fate being clearly in the hands of Inbrija for the next phase of growth." (2/15/2019)

Has Acorda Therapeutics been receiving favorable news coverage?

Media stories about ACOR stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acorda Therapeutics earned a media sentiment score of 3.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Acorda Therapeutics.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 13,740,000 shares, an increase of 8.7% from the December 15th total of 12,640,000 shares. Based on an average daily trading volume, of 2,270,000 shares, the short-interest ratio is currently 6.1 days. Currently, 29.1% of the shares of the company are short sold. View Acorda Therapeutics' Current Options Chain.

Who are some of Acorda Therapeutics' key competitors?

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include InterDigital Wireless (IDCC), Nektar Therapeutics (NKTR), Applied Materials (AMAT), Advanced Micro Devices (AMD), Celgene (CELG), Intel (INTC), Micron Technology (MU), salesforce.com (CRM), Gilead Sciences (GILD) and Western Digital (WDC).

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)
  • Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)
  • Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)
  • Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 64)

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $2.07.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $99.42 million and generates $471.43 million in revenue each year. The biopharmaceutical company earns $33.68 million in net income (profit) each year or $1.82 on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe.View Additional Information About Acorda Therapeutics.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is http://www.acorda.com/.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.


MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  409 (Vote Outperform)
Underperform Votes:  526 (Vote Underperform)
Total Votes:  935
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Featured Article: Why does a company issue an IPO?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel